Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28126549 | 0.90 | HTT (0.37) | P2RX7MAPTRXFP1TAAR1HSP90B1 | |
| SCHEMBL17351794 | 0.84 | P2RX7 (0.39) | P2RX7TAAR1HSP90B1TRAP1HSP90AA1 | |
| SCHEMBL13932536 | 0.83 | AMY1A (0.42) | P2RX7TAAR1HSP90B1TRAP1HSP90AA1 | |
| SCHEMBL18590775 | 0.83 | TAAR1 (0.45) | P2RX7TAAR1HSP90B1TRAP1HSP90AA1 | |
| SCHEMBL9921236 | 0.82 | TAAR1 (0.41) | P2RX7TAAR1HSP90B1TRAP1HSP90AA1 | |
| SCHEMBL10285184 | 0.81 | TAAR1 (0.39) | P2RX7TAAR1HSP90B1TRAP1HSP90AA1 | |
| SCHEMBL8239069 | 0.81 | TAAR1 (0.43) | MAPTRXFP1TAAR1NFE2L2SMN1; SMN2 | |
| SCHEMBL598593 | 0.79 | TAAR1 (0.44) | MAPTRXFP1TAAR1SMN1; SMN2SRC | |
| SCHEMBL17351838 | 0.79 | IDO1 (0.41) | P2RX7TAAR1HSP90B1TRAP1HSP90AA1 | |
| SCHEMBL3318682 | 0.79 | TAAR1 (0.38) | P2RX7TAAR1HSP90B1TRAP1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230303522-A1 | ARYLTETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, INSECTICIDAL AGENT CONTAINING THE COMPOUND, AND METHOD OF USE THEREOF | NIHON NOHYAKU CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230150935-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CALCIUM ION HOMEOSTASIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-18 | — | — | US | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
| US-20220251117-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1319007-B9 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | P2RX7 2998/4885MAPT 4114/4885RXFP1 3476/4885 |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | P2RX7 1103/4885MAPT 2459/4885RXFP1 4006/4885 |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | P2RX7 67/4885MAPT 681/4885RXFP1 1190/4885 |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | P2RX7 2256/4885MAPT 3539/4885RXFP1 1603/4885 |
| US-20230150935-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CALCIUM ION HOMEOSTASIS | CHERP, ATP2A1, ATP2A3 | P2RX7 278/4885MAPT 1919/4885RXFP1 1975/4885 |
| US-20230303522-A1 | ARYLTETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, INSECTICIDAL AGENT CONTAINING THE COMPOUND, AND METHOD OF USE THEREOF | CYP4Z1, DDT, AADAC | P2RX7 1115/4885MAPT 3522/4885RXFP1 1051/4885 |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | ICMT, INMT, BHMT | P2RX7 4827/4885MAPT 61/4885RXFP1 4724/4885 |
| US-20220251117-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | P2RX7 3544/4885MAPT 644/4885RXFP1 4652/4885 |
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | PKD2, PKD1, MUC1 | P2RX7 2959/4885MAPT 3562/4885RXFP1 4859/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | P2RX7 201/4885MAPT 3314/4885RXFP1 89/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | P2RX7 2928/4885MAPT 484/4885RXFP1 4406/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | P2RX7 2256/4885MAPT 3539/4885RXFP1 1603/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | P2RX7 4063/4885MAPT 2335/4885RXFP1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.